Industry News — Clinical Updates

Roslin Cells to Manufacture RPE Cells for Pfizer Wet-AMD Study

Roslin Cells (Edinburgh, Scotland) has announced that it has signed a contract with Pfizer, Inc. (New York, NY) to manufacture retinal pigment epithelium (RPE) cells for a Phase 1 trial being led by Pfizer.

The study, which is not yet open for recruitment, will evaluate the safety, feasibility, and efficacy of RPE replacement for treating wet age-related macular degeneration (AMD) patients who have rapidly progressing vision loss.

Manufacture of the cells will take place at Roslin's GMP Cellular Therapy Manufacturing Facility in Edinburgh.

Updated June 3, 2014

Designed and built in Chicago by Webitects